- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00455065
Weight Loss and Cardiovascular Disease (CVD) Prevention Via a Whole Grain Diet in Men and Women With Metabolic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fifty men and women with metabolic syndrome age 20 to 65 will be recruited to participate. Men and women are eligible if they have a body mass index (BMI) ≥ 30 and at least three out of five ATP III criteria for metabolic syndrome. These criteria are defined as: [1] Triacylglycerol ≥150 mg/dL, [2] HDL <40 mg/dL in men or <50 mg/dL in women, [3] Fasting glucose ≥100 mg/dL, [4] Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥85 mg/dL, and [5] waist circumference ≥102 cm in men or ≥88 cm in women.
Participants will receive dietary advice to either avoid whole grain foods or to have all of their grain servings each day from whole grain foods for 12 weeks. Participants will be stratified by gender and BMI and randomized using a random number table. A registered dietitian will meet individually with each participant at baseline to discuss the dietary intervention and provide educational materials. Participants in the whole grain group are given a target number of daily whole grain servings, either 4, 5, 6 or 7 servings/d, based on the number of grain servings recommended in the 2005 Dietary Guidelines For Americans for their energy needls to facilitate understanding and adherence. Participants in the whole grain group are given a list and description of whole grain foods to help them identify foods to include in their diet and were encouraged to select foods that had a whole grain food listed as the first ingredient. To ease the transition, participants in the whole grain group will consume three servings of whole grain foods per day for the first two weeks of the study and then increase to their target number of daily whole grain servings for the remaining ten weeks. Participants in the refined grain group are also given a list of whole grain foods and asked not to consume any of these foods during the study period.
In addition to the instruction on whole grain servings, participants in both groups are aasked to eat five servings of fruit and vegetables, three servings of low-fat dairy products, and two servings of lean meat, fish or poultry/d, as recommended in the 2005 Dietary Guidelines for Americans. The target macronutrient composition for all participants is 55% carbohydrate, 30% fat, with emphasis on unsaturated fats, and 15% protein. All participants are encouraged to engage in moderate physical activity at least three times a week for 30 minutes per session and were instructed to avoid dietary supplements throughout the study period. Participants in both groups are told that their aim was to lose at least 1 pound per week for the duration of the study.
Every other week, participants visit the study site and review their diet records with a dietitian on a one-on-one basis. During this time, the dietitian presents an educational lesson that explained the rationale for the dietary guidelines used in the study, and offered nutritional guidance, encouragement, and suggestions for improvement. The participant's weight, blood pressure, and waist circumference are also recorded. On the weeks that participants do not come in for a study visit, they are contacted by phone or e-mail by a dietitian to discuss their progress and address any concerns or questions. A fasting blood draw, 2-hour oral glucose tolerance test (OGTT), dual energy x-ray absorptiometery (DXA) scan, and biometric measurements are done at the beginning and end of the 12-week diet period at The Pennsylvania State University General Clinical Research Center (GCRC).
Study Type
Enrollment
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- body mass index (BMI) ≥ 30
- at least three out of five ATP III criteria for metabolic syndrome. These criteria are defined as: [1] Triacylglycerol ≥150 mg/dL, [2] HDL <40 mg/dL in men or <50 mg/dL in women, [3] Fasting glucose ≥100 mg/dL, [4] Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥85 mg/dL, and [5] waist circumference ≥102 cm in men or ≥88 cm in women.
Exclusion Criteria:
- diagnosis of type I or II diabetes
- diagnosis of CVD
- diagnosis of cancer
- diagnosis of any other serious medical condition
- use of any medications that affect glucose, insulin, cholesterol, or reproductive hormones
- smoker
- drink more than 2 alcoholic beverages/d
- consume a diet high in whole grains (>3 servings/d)
- pregnant or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Weight Loss
|
Secondary Outcome Measures
Outcome Measure |
---|
Body fat percentage
|
Blood Pressure
|
Waist Circumference
|
Lipids and Lipoproteins
|
Glucose Tolerance (OGTT)
|
Testosterone Concentration
|
Markers of Inflammation and Fibrinolysis
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Penny M Kris-Etherton, Ph.D., Penn State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB20474
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
Jordan Collaborating Cardiology GroupCardiovascular Academy; The Association of Jordanian Medical Laboratory Specialists...Not yet recruitingCardiovascular-renal-metabolic SyndromeJordan
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
Clinical Trials on Whole Grain Foods
-
USDA, Western Human Nutrition Research CenterCompletedFood PreferencesUnited States
-
USDA Beltsville Human Nutrition Research CenterCompleted
-
Purdue UniversityGrain Food FoundationRecruitingHigh Whole Grain and Low Sugar | Medium Whole Grain and Low Sugar | Low Whole Grain and Low Sugar | Low Whole Grain and High SugarUnited States
-
USDA Beltsville Human Nutrition Research CenterUnited States Department of Agriculture (USDA)Completed
-
University of CopenhagenTechnical University of DenmarkUnknownMetabolic Disease | Injury of Gastrointestinal TractDenmark
-
King's College LondonCompleted
-
University of FloridaGeneral MillsCompleted
-
Swedish University of Agricultural SciencesCompletedOverweight | Metabolic Syndrome | Impaired Glucose Tolerance | Central ObesitySweden
-
University of MinnesotaCompleted
-
Lund UniversityCompletedMetabolic Disorders and Cognitive Decline